BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million) from the Israel Innovation Authority (the “IIA”). The grant provides funding for the continued development of OpRegen®, and to date the IIA has provided annual grants totaling over $13 million.
OpRegen® is currently in a Phase I/IIa clinical study, which in March 2018 received authorization from the Data Safety Monitoring Board (DSMB) to move forward with enrollment of cohort 4. The DSMB approval was based on the safety observed throughout the first three cohorts. Safety will remain the primary focus of cohort 4. The fourth cohort will include better vision patients than the previous three cohorts. These better vision patients will likely be in earlier stages of the disease and allow for a wide range of preliminary functional assessment measurements. These earlier stage patients will likely be the target patient population for this therapy and BioTime expects to share initial data from cohort 4 in the coming months.
“The IIA’s continued support is encouraging and shows their commitment and confidence in our ability to continue the development of OpRegen, our lead cell replacement program,” said Adi Mohanty, co-Chief Executive Officer of BioTime.
About OpRegen ®
OpRegen®, which is being studied for the treatment of the dry form of AMD, consists of a suspension of retinal pigment epithelial (RPE) cells that are delivered subretinally during a simple intraocular injection. RPE cells are essential components of the back lining of the retina, and function to help nourish the retina including photoreceptors. A proprietary process that drives the differentiation of human pluripotent stem cells is used to generate high purity OpRegen® RPE cells. OpRegen® RPE cells are also “xeno-free,” meaning that no animal products are used at any point in the derivation and production process. The avoidance of the use of animal products eliminates some potential safety concerns. Preclinical studies in rats have shown that following a single subretinal injection of OpRegen®, the cells can rapidly organize into its natural monolayer structure in the subretinal space and survive throughout the lifetime of the animal. OpRegen® is designed to be an “off-the-shelf” allogeneic (non-patient specific) product. Unlike treatments that require multiple, frequent injections into the eye, it is expected that OpRegen® will be administered in a single procedure. OpRegen® was granted Fast Track designation from the FDA, which allows more frequent interactions with the agency, and eligibility for accelerated approval and priority review. OpRegen® is a registered trademark of Cell Cure Neurosciences Ltd., a majority-owned subsidiary of BioTime, Inc.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused on degenerative diseases. Its clinical programs are based on two platform technologies: cell replacement and cell/drug delivery. With its cell replacement platform, BioTime is producing new cells and tissues with its proprietary pluripotent cell technologies. These cells and tissues are developed to replace those that are either rendered dysfunctional or lost due to degenerative diseases or injuries. BioTime’s cell/drug delivery programs are based upon its proprietary HyStem® cell and drug delivery matrix technology. HyStem® was designed, in part, to provide for the transfer, retention and/or engraftment of cellular replacement therapies. BioTime’s lead cell delivery clinical program is Renevia®, which consists of HyStem® combined with the patient's own adipose (fat) progenitor cells. Renevia® met its primary endpoint in an EU pivotal clinical trial for the treatment of facial lipoatrophy in HIV patients in 2017. BioTime has submitted Renevia® for CE Mark approval in the EU. There were no device related serious adverse events reported to date. BioTime’s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy, which is in a Phase I/IIa multicenter clinical trial for the treatment of dry age-related macular degeneration, the leading cause of blindness in developing countries. There were no unexpected serious adverse events reported to date. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE American: OCX), and a private company, AgeX Therapeutics, Inc.
BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotime.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.
To receive ongoing BioTime corporate communications, please click on the following link to join the Company’s email alert list: http://news.biotime.com.
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements pertaining to product technology, clinical development, regulatory approval timelines, the success of potential cosmetic applications and potential opportunities for BioTime, Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty as to the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the “Risk Factors” section of BioTime’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. BioTime specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
David Nakasone, 510-871-4188
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Medicrea Announces Eurospine 2018 Presence and Highlights a Recently Published Study Validating Its Predictive Modelling Approach for AIS Patients20.9.2018 16:07 | Tiedote
The Medicrea Group (Euronext Growth Paris: FR0004178572 – ALMED, PEA-PME eligible, and OTCQX: MNRTY and MNRTF), pioneering the transformation of spinal surgeries through Artificial Intelligence, predictive modeling and patient specific implants with its UNiD™ ASI (Adaptive Spine Intelligence) technology, announced today that the Company is attending the Eurospine 2018 meeting taking place in Barcelona, Spain, from September 19th to 21st, where UNiD™ LAB biomedical engineers will showcase the most recent developments of the Company’s UNiD™ ASI technology. Denys Sournac, President and Chief Executive Officer, stated, “At Eurospine 2018, our team of biomedical engineers will show attending spine surgeons how the UNiD™ASI technology answers the gap left by traditional implant manufacturers through a demonstration of the UNiD™ HUB, a software platform that fully integrates surgical planning through machine learning to generate personalized implants that are adapted to each individual patien
Seoul Semiconductor Wins LED Bulb Litigation and Pursuit of Further Enforcement Actions against LED Lighting Retailers20.9.2018 16:00 | Tiedote
Seoul Semiconductor (KOSDAQ:046890) (collectively with Seoul Viosys Co., Ltd., “Seoul”), a leading global innovator of LED products and technology, announced that the U.S. Federal District Court for Nevada issued a judgment in favor of Seoul against Philcor T.V. & Electronic Leasing, Inc. dba energyavenue.com (“Philcor”), a company that sells LED lighting products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920005043/en/ Seoul Semiconductor's Key Patented Technologies (Graphic: Business Wire) Previously, Seoul filed a patent infringement lawsuit in Nevada District Court against Philcor asserting infringement of 8 LED patents. In the lawsuit, Philcor acknowledged that LED products used in the accused products were manufactured by several third party suppliers and, although previously unknown to Philcor, Philcor did not dispute that those products infringed Seoul Semiconductor’s patents. Philcor also did not dispute the
2018 Busan One Asia Festival to Take Place October 20-2820.9.2018 14:00 | Tiedote
BUSAN METROPOLITAN CITY announced that the Busan One Asia Festival (BOF) will be held from October 20th to 28th in Busan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920005024/en/ The Busan One Asia Festival (BOF) will be held from October 20th to 28th in Busan. BOF will open with a spectacular BOF Opening Performance on October 20th and end with the BOF Closing Performance on the 28th, both will be at the Busan Asiad Main Stadium. During the opening event, EXO, Wanna One, SEVENTEEN, NCT 127, Mamamoo, EXID, GFriend, and Celeb Five will show up and present wonderful K-POP performances. The closing event will have a colorful finale with performances by Red Velvet, NCT Dream, Favorite, Dynamic Duo and Rhythm Power. The photo is 2017 Busan One Asia Festival BOF Opening Performance. (Photo: Business Wire) BOF will open with a spectacular ‘BOF Opening Performance’ on October 20th and end with the ‘BOF Closing Performance’ on
L4MS Launches Its First Open Call for Cross-Border Application Experiments20.9.2018 13:30 | Tiedote
The European Project L4MS (Logistics for Manufacturing SME’s) is looking for European manufacturing SME’s and mid-caps to develop new, innovative solutions to boost their factory-floor logistic. As a Factories of the Future (FoF) project participating in I4MS (ICT for Manufacturing SMEs) and with the support of the European Union's Horizon 2020 research and innovation programme, the aim of L4MS project is to reduce the installation cost and time of mobile robots by a factor of 10. It will enable inexpensive deployment of small and flexible logistics solutions requiring no infrastructure change, no production downtime and no in-house expertise. In addition to equity-free funding, the companies will receive extensive technological support from the L4MS network. The best applicants with highest innovation potential will get access to: Matchmaking with system integrators and mobile robots manufactures, funding up to €250,000, state-of-the-art test environment within your region, mentoring
Uphold Makes Cred’s LBA Tokens Available For Purchase in 170+ Countries20.9.2018 13:00 | Tiedote
Uphold, the global digital money platform that has powered more than $3.5 billion in transactions across 184 countries, and Cred, the leader in crypto-backed credit, today announced the next step in their commercial relationship which will allow Uphold users access to LBA tokens on the Uphold platform. “Cred has secured more lending capital than any other lending company in the space by orders of magnitude,” said JP Thieriot, CEO of Uphold. “Our ability to offer Cred’s LBA token is another important milestone for our members since Cred is one of the fastest growing lending ecosystems in the crypto community. Uphold members will have access to fiat loans at a lower cost via the LBA token. Cred’s lending services can also provide a financial lifeline to the many ICO companies that have raised a significant amount of ETH and BTC and would like to receive a USD loan to diversify their balance sheets and avoid having to sell at diminished prices.” Cred and Uphold will offer two special arra
Ant Financial Launches Ant Financial Technology Brand with Full Suite of Technology Products and Services to Support Growth of Financial Institutions20.9.2018 12:43 | Tiedote
Ant Financial Services Group (“Ant Financial” or “the Company”) today announced that the Company would open up a full suite of technology products and services under a new brand, Ant Financial Technology, to support the growth of financial institutions by improving user experience and lowering costs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920005319/en/ Ant Financial launches Ant Financial Technology, a new brand supporting the growth of financial institutions, at ATEC 2018 in Hangzhou, China. (Photo: Business Wire) Announcing the launch of the Ant Financial Technology brand at the 2018 Ant Technology Exploration Conference (ATEC) in Hangzhou, Xi HU, Deputy CTO of Ant Financial said, “Since our establishment in 2014, Ant Financial has focused on developing cutting edge technologies to enable inclusive finance. We are pleased that our technology products and services have already been used to improve efficiency and
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme